NCT06186037View on ClinicalTrials.gov

Clinical Comparison of Low-dose Rosuvastatin Plus Ezetimibe Combination Therapy and High-dose Rosuvastatin Monotherapy in Patients With Minimal to Intermediate Coronary Artery Disease Without Percutaneous Coronary Intervention

PHASE4RecruitingINTERVENTIONAL
Enrollment

6,356

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

February 28, 2029

Study Completion Date

February 28, 2029

Conditions
Coronary Artery DiseaseDyslipidemiasPrimary Prevention
Interventions
DRUG

Combination drug group of Ezetimibe 10 mg/Rosuvastatin 5 mg

Oral administration once a day, taking it for 3 years

DRUG

Mono drug group of Rosuvastatin 20 mg

Oral administration once a day, taking it for 3 years

Trial Locations (1)

16247

RECRUITING

St. Vincent's Hospital, Suwon

All Listed Sponsors
lead

Saint Vincent's Hospital, Korea

OTHER